Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer.

As previously reported [ 26 ], the majority of the EGFR -mutant tumors exhibited pEGFR, with a significant trend toward an association between EGFR mutation and pEGFR (Fisher’s exact test: P = 0.0425) (Fig.

also in 6,248 other papers